Furthermore, splenic CD8 T cells from the LTS animals, treated with the combination therapy, expressed significantly higher levels of both IFN-γ and TNF-α, relative to non-tumor-bearing and control tumor-bearing mice (Fig. 7e). The gene discussed is CD8A; the disease is neoplasm.